Project Grant R01AI179943
Award Date
11/20/24
Completion Date
10/31/29
Dollars Obligated
$700K
Federal Agency
National Institute of Allergy and Infectious Diseases
Federal Grant Program
93.855
Assistance Type
Project Grant
Place of Performance
Miami, FL 33199, USA
Similar Awards
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $700,288.00 in funding to the University of South Florida to conduct research on identifying genetic factors associated with the sexual stage development of the malaria parasite Plasmodium falciparum. The project leverages a functional genomics approach using random PiggyBac mutagenesis to screen for genes...
This federal Project Grant award of $375,000.00 from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) supports research into the functions of messenger ribonucleoproteins (mRNPs) in regulating mRNA metabolism and translation in the malaria parasite Plasmodium falciparum. The research aims to identify molecular markers for distinct mRNP granules, determine their compositions, and characterize their...
This Cooperative Agreement award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), will provide $606,815.00 to Duquesne University to develop field-ready paratransgenic bacterial strains that can interfere with the ability of mosquitoes to transmit malaria parasites. The project will focus on engineering Asaia bogorensis strains that lack antibiotic resistance genes, are highly resistant to horizontal...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $813,160 Project Grant under the Allergy and Infectious Diseases Research (CFDA 93.855) program to develop mRNA-LNP vaccines targeting multiple stages and species of the human malaria parasite. The primary focus is on vaccines targeting infection by sporozoites and mosquito transmission by gametocytes of Plasmodium falciparum and P. vivax. Key vaccine candidates include PfCSP, PFS25, and PFS230 for P. falciparum, and...
This $147,656 federal Project Grant award, funded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports research to understand the role of transmembrane proteins in the cell division process of the malaria parasite Plasmodium falciparum. The award, effective January 22, 2025 through October 31, 2027, will enable the integration of biochemical and super-resolution microscopy approaches to decipher...
The federal Project Grant award of $459,131, awarded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research (CFDA 93.855) program, supports research to identify essential functions of the mitochondrion in malaria parasites. The goal is to uncover novel drug targets within the parasite mitochondrion that could lead to the development of new antimalarial treatments effective against both symptomatic and transmission stages of malaria...
This federal Project Grant award of $708,202 from the National Institute of Allergy and Infectious Diseases (NIAID) under CFDA Program 93.855 - Allergy and Infectious Diseases Research aims to discover the targets of naturally acquired protection against severe Plasmodium falciparum malaria and develop them as novel blood-stage vaccine candidates. The key products and services to be delivered include: Conducting a case-control study in Kenya to identify infants and children with severe malaria...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $1,104,050.00 in funding to The Washington University in St. Louis to investigate the mechanisms by which Plasmodium falciparum, the parasite that causes malaria, impairs the function of neutrophils, a critical component of the immune system's response to bacterial infections. The key objectives of the...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $832,071 to Seattle Children's Hospital to develop potent transmission-reducing monoclonal antibodies and optimized vaccines targeting the HAP2 and HAP2P antigens of the malaria parasite. The research aims to create a universal transmission-blocking vaccine effective against multiple Plasmodium species and overcome key...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) in the amount of $215,751 to the Regents of the University of California at Riverside. The grant will fund research to identify and characterize RNA-binding proteins (RBPs) and RNA-dependent proteins (RDPs) in the malaria parasite Plasmodium falciparum, with a focus on the parasite's sexual differentiation stage. The research aims to...